AGNC Investment (AGNC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
https://www.zacks.com/stock/news/2193841/agnc-investment-agnc-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2193841
Dec 05, 2023 - In the most recent trading session, AGNC Investment (AGNC) closed at $9, indicating a -0.88% shift from the previous trading day.
0
Bernstein names Amazon its 'best idea' for internet stocks in 2024. We see a lot to like, too
https://www.cnbc.com/2023/12/05/bernstein-names-amazon-its-best-idea-and-we-see-a-lot-to-like-too-.html
Dec 05, 2023 - Club holding Amazon (AMZN) is a stock to own going into 2024, with the ecommerce giant poised for further profitability, according to Bernstein Research.
0
Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2193633/wall-street-analysts-see-a-42-55-upside-in-krystal-biotech-inc-krys-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2193633
Dec 05, 2023 - The mean of analysts' price targets for Krystal Biotech, Inc. (KRYS) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Barclays cuts ImmunoGen to equal weight, doesn't see more bidders
https://seekingalpha.com/news/4043124-barclays-cuts-immunogen-to-equal-weight-doesnt-see-more-bidders?source=feed_sector_healthcare
Dec 04, 2023 - Barclays downgraded ImmuoGen (IMGN) to equal weight, stating that it doesn't see any other bidders emerging in the wake of AbbVie’s $10B offer for the company. Read more here.
0
RBC sees Sarepta's Elevidys remaining on market: report
https://seekingalpha.com/news/4043108-rbc-sees-sareptas-elevidys-remaining-on-market-report?source=feed_sector_healthcare
Dec 04, 2023 - RBC said it was highly likely that the FDA will allow Sarepta's (SRPT) drug Elevidys for Duchenne muscular dystrophy to remain on the market. Read more here.
0
Piper sees GLP-1s increasing demand for knee/hip surgeries near-term
https://seekingalpha.com/news/4042633-piper-sees-glp-1-drugs-increasing-demand-for-knee-hip-surgeries-near-term?source=feed_sector_healthcare
Dec 03, 2023 - Piper Sandler said it expects upcoming results from a Novo Nordisk (NVO) study of its weight-loss drug semaglutide in the treatment of osteoarthritis to be “med
0
AES Sees Years of Growth Ahead as It Invests More in Clean Energy
https://www.fool.com/investing/2023/12/03/aes-sees-years-of-growth-clean-energy/?source=iedfolrf0000001
Dec 03, 2023 - There's a solid runway for continued growth.
0
Plug Power surges to top industrial gainer of week, Kanzhun sees No. 1 loser tag
https://seekingalpha.com/news/4042564-plug-power-surges-top-industrial-gainer-week-kanzhun-sees-no-1-loser-tag?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Dec 02, 2023 - The top five gainers in the industrial sector (stocks with a market cap of over $2B) all gained more than +12% each for the week ending Dec. 1. Read more here
0
Case for gold fever: NewEdge Wealth sees record rush intensifying
https://www.cnbc.com/2023/12/02/case-for-gold-fever-newedge-wealth-sees-record-rush-intensifying-.html
Dec 02, 2023 - "It's been a pretty strong performance for gold — especially when there is a rally in the stock market in November," NewEdge Wealth's Ben Emons said.
0
Investors piled cash into money market mutual funds in 2023 and now could see a higher tax bill
https://www.cnbc.com/2023/12/01/money-market-funds-may-deliver-a-surprise-tax-bill-amid-higher-yields.html
Dec 01, 2023 - If you funneled cash into money market mutual funds in 2023 amid rising interest rates, you may have a surprise tax bill in April, experts say.
0